Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QH104
- Development stage
- Phase 2
- Lead developer
- Beijing Qinghui Liannuo Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal
01
Overview
QH104 is an allogeneic B7H3-targeting CAR-γδT cell therapy. It consists of a subset of allogeneic T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) which have been engineered to target B7-H3 (CD276) positive tumors. The therapy is administered via intrathecal injection for the treatment of B7H3-positive tumors, particularly recurrent glioblastoma (rGBM) and meningeal metastases from B7H3+ solid tumors.
- Other names
- Allogeneic anti-B7-H3 CAR gamma delta T cells QH104Allogenic B7H3 CAR-γδT cell
02
Targets
B7-H3
Beyond the preview
Go deeper on QH104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QH104.